Updated
InnovivaINVA · Healthcare
$18.88-0.63%
Market cap$1.4B
IndustryBiotechnology

Innoviva (INVA) Superinvestor holders

16 of the superinvestors we track hold Innoviva (INVA) in their latest 13F filings, $289M in total.

Summary

The largest holder is Jim Simons (Renaissance Technologies), with $92M, 0.1% of the portfolio.

In their latest quarter: 3 added, 11 trimmed.

Who holds it

Each investor's latest 13F filing, largest stake first. What a 13F shows.

InvestorLast changeSharesValue% of portfolioFiled for
Jim Simons
Renaissance Technologies
Trimmed 4,036,532$92M 0.1%Q2 2026
Mark Donovan
Boston Partners
Added 1,927,959$44M 0.0%Q2 2026
Alex Denner
Sarissa Capital Management
Trimmed 1,890,604$43M 24.1%Q2 2026
Paul Marshall
Marshall Wace
Trimmed 1,454,319$33M 0.0%Q2 2026
Chuck Royce
Royce Investment Partners
Trimmed 1,118,257$24M 0.2%Q3 2026
Two Sigma
Two Sigma Investments
Trimmed 1,032,807$23M 0.0%Q2 2026
Cliff Asness
AQR Capital Management
Added 549,553$12M 0.0%Q2 2026
Arrowstreet Capital Trimmed 340,168$8M 0.0%Q2 2026
David Shaw
D. E. Shaw & Co.
Trimmed 166,255$4M 0.0%Q2 2026
Joel Greenblatt
Gotham Asset Management
Trimmed 78,386$2M 0.0%Q2 2026
David Vogel
Voloridge Investment Management
Trimmed 72,529$2M 0.0%Q2 2026
Josef Lakonishok
LSV Asset Management
Held 66,323$1M 0.0%Q3 2026
Jennison Associates Trimmed 53,651$1M 0.0%Q2 2026
Alan Howard
Brevan Howard
Added 17,186$390,294 0.0%Q2 2026
Didric Cederholm
Lion Point Capital
Held 8,200$186,222 0.9%Q2 2026
Ensign Peak
Ensign Peak Advisors
Trimmed 5,700$129,447 0.0%Q2 2026

Holders by quarter

QuarterSuperinvestors holding it
Q2 202617
Q1 202619
Q4 202519
Q3 202514
Q2 202515
Q1 202514
Q4 202414
Q3 202414

Questions about Innoviva

Which superinvestors own Innoviva?

16 of the superinvestors we track hold Innoviva (INVA) in their latest 13F filings, $289M in total. Jim Simons, Mark Donovan, Alex Denner, Paul Marshall, Chuck Royce, Two Sigma.

Who is the largest superinvestor holder of INVA?

The largest holder is Jim Simons (Renaissance Technologies), with $92M, 0.1% of the portfolio.

From Innoviva's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.

Investingly

Better research starts here.

Every filing, chart and insider trade behind Innoviva and thousands of other companies, in one place. Free to start.